Literature DB >> 8966999

Detection of ehrlichial antigen in plasma of beagle dogs with experimental acute Ehrlichia canis infection.

T Waner1, M Rosner, S Harrus, A Naveh, R Zass, A Keysary.   

Abstract

Six beagles were experimentally infected with Ehrlichia canis. All dogs developed typical clinical signs of ehrlichiosis and sero-converted. Ehrlichial antigenemia in the plasma of the infected dogs was detected using a sandwich enzyme-linked immunosorbent assay (ELISA). Ehrlichial antigen was present starting 15-20 days post-infection, after the development of clinical signs and antibody titre to Ehrlichia canis. The appearance of ehrlichial antigen in the plasma for a relatively short and variable period after the clinical and haematological signs, limits its potential as an early diagnostic prognosticator of canine ehrlichiosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8966999     DOI: 10.1016/0304-4017(95)00902-7

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  4 in total

1.  Coinfection with multiple tick-borne and intestinal parasites in a 6-week-old dog.

Authors:  Arnon Gal; Shimon Harrus; Itamar Arcoh; Eran Lavy; Itzhak Aizenberg; Yael Mekuzas-Yisaschar; Gad Baneth
Journal:  Can Vet J       Date:  2007-06       Impact factor: 1.008

2.  Serodetection of Ehrlichia canis infection in dogs from Ludhiana district of Punjab, India.

Authors:  L D Singla; Harkirat Singh; P Kaur; N D Singh; N K Singh; P D Juyal
Journal:  J Parasit Dis       Date:  2011-08-02

3.  Doxycycline hyclate treatment of experimental canine ehrlichiosis followed by challenge inoculation with two Ehrlichia canis strains.

Authors:  E B Breitschwerdt; B C Hegarty; S I Hancock
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  [Vector-borne parasites of dogs on the Islands of Cabo Verde].

Authors:  Marlene Kirchner; Adrian Brunner; Renate Edelhofer; Anja Joachim
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.